A meta-analysis of randomized trials looked at how adding the medication blinatumomab to standard chemotherapy affects children with B-cell acute lymphoblastic leukemia (B-ALL). This specific group includes children whose cancer has returned or who have high-risk cases. The study focused on survival rates and how well the treatment cleared signs of the disease.
The results showed that children who received blinatumomab along with chemotherapy had better disease-free survival and overall survival compared to those receiving only chemotherapy. While the study did not find a significant difference in the rate of minimal residual disease clearance, the survival improvements were statistically significant.
Safety data showed that the rates of adverse events were similar between the two groups. However, it is important to note that there is currently limited evidence regarding its use in all frontline cases. Because of variations in how toxicity and disease clearance were reported, these results should be discussed with a specialist to understand how they apply to a specific patient.
